DGAP-News

MOLOGEN presents first anti-tumor data of the product candidate and TLR9 agonist EnanDIM(R) in a murine tumor model - Seite 2

structure, no chemical modification is needed in order to protect the
molecules against degradation by enzymes.

The EnanDIM(R) ISR promise a broad activation of the immune system with a
good safety and tolerability profile. Due to their characteristic mechanism
of action, EnanDIM(R) molecules have the potential to be applied in various
cancer indications. Additionally, it may be possible to develop selected
members of the EnanDIM(R) family both for monotherapy and in combination
with targeted forms of treatment, such as checkpoint inhibitors and other
immunotherapeutic approaches. Moreover, different members of the EnanDIM(R)
family may also be used in the area of infectious diseases - including HIV.

The data will be presented at the Second CRI-CIMT-EATI-AACR International
Cancer Immunotherapy Conference in New York, USA (September 25-28, 2016).
The conference will be organized by the Cancer Research Institute (CRI),
die Association for Cancer lmmunotherapy (CIMT), the European Academy of
Tumor Immunology (EATI), and the American Association for Cancer Research
(AACR).

Abstract details:
Abstract number: # 278
Title: "Preclinical data of novel enantiomeric oligonucleotides for cancer
immunotherapy: The TLR9 agonist EnanDIM"
Poster presentation: September 26, from 5:15-7:45 pm
Poster Number: B067

For more information on the Second CRI-CIMT-EATI-AACR International Cancer
Immunotherapy Conference please visit the website: http://www.aacr.org.


About EnanDIM(R)
EnanDIM(R) (Enantiomeric, DNA-based, ImmunoModulator) is an innovative
linear DNA-based TLR9 agonist in pre-clinical development. It broadly and
strongly activates the immune system. EnanDIM(R) could be used in various
cancer indications either as monotherapy, in combination with other
targeted therapies or immune modulators, such as so called checkpoint
inhibitors, or with other immunotherapeutic approaches. It could also
potentially be used in the field of infectious diseases.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy lefitolimod (MGN1703) is the company's lead
product and best-in-class TLR9 agonist. Treatment with lefitolimod
(MGN1703) triggers a broad and strong activation of the immune system. Due
to this mode of action, namely to reactivate the monitoring function of the